 Grifols MCE: GRF, MCE: GRF.P, NASDAQ: GRFS, a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing peoples health and well-being, today announced the start of production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the first specific drug developed to combat COVID-19. 